MX2014015986A - Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina. - Google Patents

Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina.

Info

Publication number
MX2014015986A
MX2014015986A MX2014015986A MX2014015986A MX2014015986A MX 2014015986 A MX2014015986 A MX 2014015986A MX 2014015986 A MX2014015986 A MX 2014015986A MX 2014015986 A MX2014015986 A MX 2014015986A MX 2014015986 A MX2014015986 A MX 2014015986A
Authority
MX
Mexico
Prior art keywords
cell
malignant cancers
lymphoma
cell malignant
treating lymphoma
Prior art date
Application number
MX2014015986A
Other languages
English (en)
Spanish (es)
Inventor
Francesco Bertoni
Paola Bonetti
Original Assignee
Oncoethix Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoethix Gmbh filed Critical Oncoethix Gmbh
Publication of MX2014015986A publication Critical patent/MX2014015986A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MX2014015986A 2012-06-25 2013-06-25 Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina. MX2014015986A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261663885P 2012-06-25 2012-06-25
US201261670918P 2012-07-12 2012-07-12
PCT/EP2013/063313 WO2014001356A1 (en) 2012-06-25 2013-06-25 Method of treating lymphoma using thienotriazolodiazepine compounds

Publications (1)

Publication Number Publication Date
MX2014015986A true MX2014015986A (es) 2016-02-11

Family

ID=48672651

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014015986A MX2014015986A (es) 2012-06-25 2013-06-25 Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina.

Country Status (12)

Country Link
US (1) US20140018353A1 (ja)
EP (1) EP2863923B1 (ja)
JP (1) JP6265979B2 (ja)
KR (1) KR20150045423A (ja)
CN (1) CN105050605A (ja)
AU (1) AU2013283378B2 (ja)
BR (1) BR112014032105A2 (ja)
CA (1) CA2877434A1 (ja)
IN (1) IN2014DN11269A (ja)
MX (1) MX2014015986A (ja)
RU (1) RU2659171C2 (ja)
WO (1) WO2014001356A1 (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3608317A1 (en) 2012-01-12 2020-02-12 Yale University Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
EP2970282B1 (en) 2013-03-15 2019-08-21 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
ES2635560T3 (es) 2013-07-08 2017-10-04 Incyte Holdings Corporation Heterociclos tricíclicos como inhibidores de la proteína NET
KR20160036591A (ko) * 2013-08-01 2016-04-04 온코에틱스 게엠베하 티에노트리아졸로디아제핀 화합물을 함유하는 약학적 제제
WO2015018520A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa A bet-brd inhibitor represents a novel agent for alk positive anaplastic large cell lymphoma
EP3030242A1 (en) * 2013-08-06 2016-06-15 Oncoethix GmbH Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor
WO2015018522A1 (en) * 2013-08-06 2015-02-12 Oncoethix Sa Bet-bromodomain inhibitor shows synergism with several anti-cancer agents in pre-clinical models of diffuse large b-cell lymphoma (dlbcl)
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
EP3074018A1 (en) * 2013-11-27 2016-10-05 Oncoethix GmbH Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
WO2015095492A1 (en) 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
CN106414442B (zh) 2014-04-23 2019-03-15 因赛特公司 作为BET蛋白抑制剂的1H-吡咯并[2,3-c]吡啶-7(6H)-酮和吡唑并[3,4-c]吡啶-7(6H)-酮
US20170095484A1 (en) * 2014-05-02 2017-04-06 Oncoethix Gmbh Method of treating resistant non-hodgkin lymphoma, medulloblastoma, and/or alk+non-small cell lung cancer using thienotriazolodiazepine compounds
EP3137085A4 (en) 2014-05-02 2017-12-27 Oncoethix GmbH Method of treating acute myeloid leukemia and/or acute lymphoblastic leukemia using thienotriazolodiazepine compounds
RU2016147946A (ru) 2014-05-08 2018-06-08 Онкоэтикс Гмбх Способ лечения трижды негативного рака молочной железы с использованием тиенотриазолодиазепиновых соединений
AU2015273032A1 (en) 2014-06-13 2016-12-15 Oncoethix Gmbh Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds
JP2017528446A (ja) * 2014-08-19 2017-09-28 オンコエシックス ゲーエムベーハー チエノトリアゾロジアゼピン化合物を用いるリンパ腫の治療方法
TWI712603B (zh) 2014-09-15 2020-12-11 美商英塞特公司 作為ｂｅｔ蛋白抑制劑之三環雜環
KR101675984B1 (ko) 2015-02-23 2016-11-14 한양대학교 에리카산학협력단 티에노디아제핀 유도체 또는 이의 약학적으로 허용가능한 염, 및 이를 유효성분으로 포함하는 약학적 조성물
CN108601764A (zh) 2015-03-18 2018-09-28 阿尔维纳斯股份有限公司 用于靶蛋白的增强降解的化合物和方法
US10683305B2 (en) 2015-04-27 2020-06-16 Concert Pharmaceuticals, Inc. Deuterated OTX-015
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
AR106520A1 (es) 2015-10-29 2018-01-24 Incyte Corp Forma sólida amorfa de un inhibidor de proteína bet
PE20190623A1 (es) 2016-06-20 2019-04-26 Incyte Corp Formas solidas cristalinas de un inhibidor de bet
US11220515B2 (en) 2018-01-26 2022-01-11 Yale University Imide-based modulators of proteolysis and associated methods of use
CN108070562A (zh) * 2018-02-03 2018-05-25 金华市中心医院 一种“双打击”弥漫大b细胞淋巴瘤细胞系制备方法
CN118480030A (zh) 2018-04-13 2024-08-13 阿尔维纳斯运营股份有限公司 小脑蛋白配体和包括其的双官能化合物
TW202136240A (zh) 2019-12-19 2021-10-01 美商亞文納營運公司 用於靶向降解雄激素受體之化合物及方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0661284A1 (en) 1992-09-18 1995-07-05 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compound and medicinal use thereof
CN1109037C (zh) * 1996-09-13 2003-05-21 三菱制药株式会社 噻吩并－三唑并二氮杂䓬化合物及其医药用途
CA2710740C (en) * 2007-12-28 2016-07-19 Shinji Miyoshi Thienotriazolodiazepine compound as antitumor agent
PT2571503E (pt) * 2010-05-14 2015-04-29 Dana Farber Cancer Inst Inc Composições e a sua utilização no tratamento de neoplasia, doença inflamatória e outros distúrbios
JP5715241B2 (ja) * 2010-05-14 2015-05-07 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 新生物、炎症性疾患、およびその他の障害を治療するための組成物および方法
WO2013033420A1 (en) * 2011-08-30 2013-03-07 Whitehead Institute For Biomedical Research Methods of downregulating translocated oncogene expression using bromodomain inhibitors

Also Published As

Publication number Publication date
CA2877434A1 (en) 2014-01-03
WO2014001356A1 (en) 2014-01-03
AU2013283378B2 (en) 2017-07-13
AU2013283378A1 (en) 2015-01-29
CN105050605A (zh) 2015-11-11
RU2015101106A (ru) 2016-08-10
JP6265979B2 (ja) 2018-01-24
JP2015531747A (ja) 2015-11-05
IN2014DN11269A (ja) 2015-10-09
KR20150045423A (ko) 2015-04-28
RU2659171C2 (ru) 2018-06-28
EP2863923B1 (en) 2019-05-08
US20140018353A1 (en) 2014-01-16
BR112014032105A2 (pt) 2017-08-01
EP2863923A1 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
MX2014015986A (es) Metodo para tratar linfoma utilizando compuestos de tienotriazolodiazepina.
MX370814B (es) Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
PH12016502354A1 (en) Pharmaceutical composition
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
NZ631144A (en) Compositions and methods for transmucosal absorption
MX2013010770A (es) Tratamiento de tumores solidos.
GEP201706624B (en) Triazolopyrazine as brd4 inhibitors and usage thereof for cancer treatment
MX365525B (es) Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
MX347765B (es) Inhibidores macrociclicos de la quinasa flt3.
PH12014501829A1 (en) Bicyclic pyrazinone derivatives
MX2014012477A (es) Inhibidores pirrolopirazona de tanquirasa.
MX2014013090A (es) Derivados de pirrolotriazinona.
PH12015501088A1 (en) Dimeric compounds
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
MD4538C1 (ro) 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei
MX360409B (es) Terapia de combinacion de dosis fija para la enfermedad de parkinson.
PH12015500399A1 (en) Azaindolines
MX2014014816A (es) Composicion farmaceutica para tratar inflamacion y dolor.
MX2013006184A (es) Compuestos de oxazol [5, 4-b]piridin-5-ilo y su uso para el tratamiento de cancer.
PH12015501980A1 (en) Pyrroloquinolinyl-pyrrolidine-2,5-dione formulations and methods for preparing and using same